March 12, 2012
Novartis Pharma and Alcon Japan announced on March 9 that Novartis will transfer marketing rights for the anti-allergic ophthalmic agent Zaditen Ophthalmic Solution 0.05% and UD0.05% (ketotifen fumarate) to Alcon Japan as of April 2. Alcon Japan will be responsible...read more